IL231787A - History of uridine diphosphate, their preparations and their use in the treatment of neurodegenerative diseases - Google Patents

History of uridine diphosphate, their preparations and their use in the treatment of neurodegenerative diseases

Info

Publication number
IL231787A
IL231787A IL231787A IL23178714A IL231787A IL 231787 A IL231787 A IL 231787A IL 231787 A IL231787 A IL 231787A IL 23178714 A IL23178714 A IL 23178714A IL 231787 A IL231787 A IL 231787A
Authority
IL
Israel
Prior art keywords
compositions
neurodegenerative disorders
treating neurodegenerative
uridine diphosphate
diphosphate derivatives
Prior art date
Application number
IL231787A
Other languages
English (en)
Hebrew (he)
Other versions
IL231787A0 (en
Original Assignee
Univ Tufts
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Tufts filed Critical Univ Tufts
Publication of IL231787A0 publication Critical patent/IL231787A0/en
Publication of IL231787A publication Critical patent/IL231787A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C07H19/10—Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65586—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system at least one of the hetero rings does not contain nitrogen as ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6564—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms
    • C07F9/6571—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and oxygen atoms as the only ring hetero atoms
    • C07F9/6574—Esters of oxyacids of phosphorus
    • C07F9/65742—Esters of oxyacids of phosphorus non-condensed with carbocyclic rings or heterocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6564—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms
    • C07F9/6571—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and oxygen atoms as the only ring hetero atoms
    • C07F9/6574—Esters of oxyacids of phosphorus
    • C07F9/65744—Esters of oxyacids of phosphorus condensed with carbocyclic or heterocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C07H17/02—Heterocyclic radicals containing only nitrogen as ring hetero atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/20—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL231787A 2011-09-30 2014-03-27 History of uridine diphosphate, their preparations and their use in the treatment of neurodegenerative diseases IL231787A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161541919P 2011-09-30 2011-09-30
PCT/US2012/058080 WO2013049686A1 (en) 2011-09-30 2012-09-28 Uridine diphosphate derivatives, compositions and methods for treating neurodegenerative disorders

Publications (2)

Publication Number Publication Date
IL231787A0 IL231787A0 (en) 2014-05-28
IL231787A true IL231787A (en) 2017-05-29

Family

ID=47996472

Family Applications (1)

Application Number Title Priority Date Filing Date
IL231787A IL231787A (en) 2011-09-30 2014-03-27 History of uridine diphosphate, their preparations and their use in the treatment of neurodegenerative diseases

Country Status (9)

Country Link
US (6) US8598141B2 (enExample)
EP (1) EP2760858B1 (enExample)
JP (1) JP6162125B2 (enExample)
CN (2) CN107353316B (enExample)
AU (1) AU2012315671B2 (enExample)
CA (1) CA2850367C (enExample)
IL (1) IL231787A (enExample)
IN (1) IN2014CN03043A (enExample)
WO (1) WO2013049686A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2850367C (en) * 2011-09-30 2021-06-01 Tufts University Uridine diphosphate derivatives, compositions and methods for treating neurodegenerative disorders
US9163055B2 (en) * 2012-09-28 2015-10-20 Tufts University Methods for treating glaucoma using uridine diphosphate derivatives
US10138265B2 (en) 2013-03-13 2018-11-27 Tufts University Uridine nucleoside derivatives, compositions and methods of use
SI2968385T1 (sl) 2013-03-13 2018-10-30 Tufts University Uridin nukleozid derivati, sestavki in metode uporabe
US10526287B2 (en) 2015-04-23 2020-01-07 Constellation Pharmaceuticals, Inc. LSD1 inhibitors and uses thereof
SG11201707513QA (en) 2015-05-29 2017-10-30 Univ Leland Stanford Junior Nucleoside agents for the reduction of the deleterious activity of extended nucleotide repeat containing genes
JP7121731B2 (ja) * 2016-09-26 2022-08-18 タフツ・ユニバーシティ ウリジンヌクレオシド誘導体、組成物及び使用方法
TWI753037B (zh) 2016-10-26 2022-01-21 美商星座製藥公司 Lsd1抑制劑及其用途
EP4190334A1 (en) * 2018-06-14 2023-06-07 Mayo Foundation for Medical Education and Research Methods and materials for treating glycosylation disorders
WO2021194959A1 (en) * 2020-03-24 2021-09-30 Gliaguard, Inc. Treatment of eye disorders with uridine phosphate derivatives

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0621073B2 (ja) 1986-03-06 1994-03-23 日水製薬株式会社 中枢抑制剤
JP3032053B2 (ja) 1991-09-06 2000-04-10 日水製薬株式会社 ウリジン誘導体及びこれを含有する医薬
US5962459A (en) 1996-05-28 1999-10-05 Polifarma S.P.A. Therapeutic active agent for treatment of neuron degenerative diseases
EP1011688B1 (en) 1997-08-29 2005-02-02 The University of North Carolina at Chapel Hill Use of uridine 5'-diphosphate and analogs thereof for the treatment of lung diseases
US20050203053A1 (en) 1999-07-30 2005-09-15 Wurtman Richard J. Uridine administration improves phosphatide synthesis, synaptic transmission and cogntive function
US20070004670A1 (en) 1998-07-31 2007-01-04 Richard Wurtman Compositions containing citicoline, and methods of use thereof
US8143234B2 (en) 1998-07-31 2012-03-27 Massachusetts Institute Of Technology Uridine administration improves phosphatide synthesis, synaptic transmission and cognitive function
US8518882B2 (en) 1998-07-31 2013-08-27 Massachusetts Institute Of Technology Methods and compositions for ameliorating or inhibiting decline in memory or intelligence or improving same
DK1140104T3 (da) 1998-07-31 2008-01-21 Massachusetts Inst Technology Behandling af Alzheimer's sygdom ved forögelse af cytidinniveauer in vivo
US8314064B2 (en) * 1998-07-31 2012-11-20 Massachusetts Institute Of Technology Uridine administration stimulates membrane production
US20060069061A1 (en) 1998-07-31 2006-03-30 Dick Wurtman Compositions containing uridine and choline, and methods utilizing same
GB0004297D0 (en) 2000-02-23 2000-04-12 Ucb Sa 2-oxo-1 pyrrolidine derivatives process for preparing them and their uses
US6875751B2 (en) 2000-06-15 2005-04-05 Idenix Pharmaceuticals, Inc. 3′-prodrugs of 2′-deoxy-β-L-nucleosides
US20050074819A1 (en) * 2003-10-01 2005-04-07 Japan Health Sciences Foundation Screening method of drug for treatment of neuropathic pain
EP1765075A4 (en) 2004-06-10 2010-11-10 Mclean Hospital Corp PYRIMIDINES, AS FORM. uridine; IN THE TREATMENT OF PATIENTS WITH MANIC-DEPRESSIVE PSYCHOSIS
US7851456B2 (en) 2005-06-29 2010-12-14 Inspire Pharmaceuticals, Inc. P2Y6 receptor agonists for treating lung diseases
EP2136626A4 (en) 2007-03-19 2011-02-23 Oregon State Mannich base n-oxide drugs
US7964580B2 (en) 2007-03-30 2011-06-21 Pharmasset, Inc. Nucleoside phosphoramidate prodrugs
AU2009298802A1 (en) 2008-09-23 2010-04-08 Alnylam Pharmaceuticals, Inc. Chemical modifications of monomers and oligonucleotides with cycloaddition
US9221868B2 (en) 2010-12-01 2015-12-29 Bar-Ilan University Uridine di- or tri-phosphate derivatives and uses thereof
CA2850367C (en) 2011-09-30 2021-06-01 Tufts University Uridine diphosphate derivatives, compositions and methods for treating neurodegenerative disorders
US9163055B2 (en) 2012-09-28 2015-10-20 Tufts University Methods for treating glaucoma using uridine diphosphate derivatives
SI2968385T1 (sl) * 2013-03-13 2018-10-30 Tufts University Uridin nukleozid derivati, sestavki in metode uporabe
US10138265B2 (en) 2013-03-13 2018-11-27 Tufts University Uridine nucleoside derivatives, compositions and methods of use

Also Published As

Publication number Publication date
EP2760858A1 (en) 2014-08-06
JP2014528418A (ja) 2014-10-27
CA2850367A1 (en) 2013-04-04
EP2760858A4 (en) 2015-04-22
JP6162125B2 (ja) 2017-07-12
US20130252919A1 (en) 2013-09-26
CN107353316B (zh) 2020-08-18
US8598141B2 (en) 2013-12-03
IN2014CN03043A (enExample) 2015-07-03
US20150045319A1 (en) 2015-02-12
US8785620B2 (en) 2014-07-22
US20160318968A1 (en) 2016-11-03
AU2012315671B2 (en) 2017-07-20
CN103906745A (zh) 2014-07-02
CN107353316A (zh) 2017-11-17
WO2013049686A1 (en) 2013-04-04
AU2012315671A1 (en) 2014-04-17
EP2760858B1 (en) 2018-08-08
US11072627B2 (en) 2021-07-27
US20210347807A1 (en) 2021-11-11
US9227993B2 (en) 2016-01-05
US20190309009A1 (en) 2019-10-10
CN103906745B (zh) 2017-08-25
IL231787A0 (en) 2014-05-28
US20140066613A1 (en) 2014-03-06
CA2850367C (en) 2021-06-01

Similar Documents

Publication Publication Date Title
IL231787A (en) History of uridine diphosphate, their preparations and their use in the treatment of neurodegenerative diseases
PL2672966T3 (pl) Kompozycja farmaceutyczna, sposoby leczenia i jej zastosowania
PL2675294T3 (pl) Glukozylowa kompozycja stewii
IL238416A0 (en) Preparations and methods for the treatment of diseases caused by protein pathology
DK3292875T3 (en) Compositions and methods for treating diseases
IL238067A0 (en) Compositions, structures and methods for neural regeneration
IL232710A0 (en) l-serine preparations, methods and uses for the treatment of neurodegenerative diseases and disorders
IL231158A0 (en) Preparations and methods for the treatment of neurodegenerative diseases
IL231157A0 (en) Preparations and methods for the treatment of neurodegenerative diseases
EP2897689A4 (en) COMPOSITIONS AND METHODS OF TREATING ALOPEZIA
IL238223A0 (en) Methods and materials for the treatment of multiple sclerosis and diseases related to it
PL2729008T3 (pl) Systemy, sposoby i formulacje do leczenia raka
PL2768320T3 (pl) Glukozylowa kompozycja na bazie stewii
EP2869821A4 (en) COMPOSITIONS AND METHODS FOR TREATING AND INHIBITING VIRAL INFECTIONS
IL236636A0 (en) Difluorolactam formulations for ep4-mediated bone-related conditions and diseases
IL228705A (en) Derivatives of Reliable Phenoxy-Ethyl, Pharmaceutical Preparations Containing and Using Them
AP2013007056A0 (en) Methods and compositions for treating kidney disorders
SG10201602487SA (en) Agent for improving or maintaining qol
ZA201309630B (en) Film-forming composition, and use thereof for treating herpes
IL218215A (en) Dihydro-Oxazolobenzodiazepinone Derivatives, Processes for their Preparation, Pharmaceutical Preparations Including and Using Them
PL2838903T3 (pl) Sposoby i kompozycje do leczenia zakażeń wirusowych
SG11201402899TA (en) Methods and compositions for treating viral diseases
SG10201500715XA (en) Composition for Multiple Health Benefits and Methods Thereof
PT3539540T (pt) Inibidor de sglt2 1-cloro-4-(beta-d-glucopiranos-1-il)-2-[4-((s)-tetra-hidrofurano-3-iloxi)-benzil]-benzeno em combinação com insulina para utilização num método para redução do risco de hipoglicemia
PL395177A1 (pl) Nowe karboamidowe pochodne dekstrometorfanu i sposób ich wytwarzania

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed